{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:54:09Z","timestamp":1794956049939,"version":"4.9.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":5370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.jpainsymman.2005.01.004","type":"journal-article","created":{"date-parts":[[2005,6,15]],"date-time":"2005-06-15T03:50:48Z","timestamp":1118807448000},"page":"10-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":145,"special_numbering":"S","title":["Opioid Metabolites"],"prefix":"10.1016","volume":"29","author":[{"given":"J\u00f6rn","family":"L\u00f6tsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2005.01.004_bib1","first-page":"1","article-title":"Human UGT2B7 catalyzes morphine glucuronidation","volume":"25","author":"Coffman","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1440-1681.1998.t01-19-.x","article-title":"Glucuronidation of dihydrocodeine by human liver microsomes and the effect of inhibitors","volume":"25","author":"Kirkwood","year":"1998","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib3","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7326\/0003-4819-86-6-738","article-title":"Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer","volume":"86","author":"Szeto","year":"1977","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0024-3205(95)00010-4","article-title":"Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes","volume":"56","author":"Mignat","year":"1995","journal-title":"Life Sci"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cpt197824160","article-title":"Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics","volume":"24","author":"Findlay","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00008571-199512000-00001","article-title":"The pharmacogenetics of codeine hypoalgesia","volume":"5","author":"Sindrup","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF00280101","article-title":"Impact of environmental and genetic factors on codeine analgesia","volume":"41","author":"Desmeules","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1365-2125.1995.tb04428.x","article-title":"Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan","volume":"39","author":"Persson","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s002280050491","article-title":"Codeine in post-operative pain. Study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide","volume":"54","author":"Poulsen","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0304-3959(93)90229-I","article-title":"Are poor metabolisers of sparteine\/debrisoquine less pain tolerant than extensive metabolisers?","volume":"53","author":"Sindrup","year":"1993","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib11","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0022-3565(25)20766-2","article-title":"Pharmacogenetic determination of the effects of codeine and prediction of drug interactions","volume":"278","author":"Caraco","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/clpt.1982.151","article-title":"Codeine disposition in smokers and nonsmokers","volume":"32","author":"Rogers","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF00316466","article-title":"Analgesic effect and plasma concentrations of codeine and morphine after two dose levels of codeine following oral surgery","volume":"44","author":"Quiding","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1742-1241.2000.tb11929.x","article-title":"Codeine analgesia is due to codeine-6-glucuronide, not morphine","volume":"54","author":"Vree","year":"2000","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1023\/A:1016059618633","article-title":"Analgesic and immunomodulatory effects of codeine and codeine 6-glucuronide","volume":"13","author":"Srinivasan","year":"1996","journal-title":"Pharm Res"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0009-9236(95)90049-7","article-title":"Dihydrocodeine: A new opioid substrate for the polymorphic CYP2D6 in humans","volume":"58","author":"Fromm","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1034\/j.1600-0773.2002.910203.x","article-title":"Affinities of dihydrocodeine and its metabolites to opioid receptors","volume":"91","author":"Schmidt","year":"2002","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2125.1998.00727.x","article-title":"The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers","volume":"45","author":"Wilder-Smith","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00003088-200140070-00001","article-title":"Morphine-6-glucuronide: an analgesic of the future?","volume":"40","author":"L\u00f6tsch","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib20","unstructured":"Kamata O, Watanabe S, Ishii S, et al. Analgesic effect of morphine glucuronides. In: Proc. 89th Meeting Pharmacology Society Japan, 1969, p. 443."},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib21","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/0024-3205(88)90479-1","article-title":"Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats","volume":"43","author":"Abbott","year":"1988","journal-title":"Life Sci"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib22","first-page":"477","article-title":"Morphine-6-glucuronide is more mu-selective and potent in analgesic tests than morphine","volume":"328","author":"Frances","year":"1990","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-3565(25)20832-1","article-title":"Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite","volume":"251","author":"Paul","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib24","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/00000542-198912000-00018","article-title":"Ventilatory effects of fourth cerebroventricular infusions of morphine-6- or morphine-3-glucuronide in the awake dog","volume":"71","author":"Pelligrino","year":"1989","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0169-328X(97)00353-7","article-title":"mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality","volume":"54","author":"Loh","year":"1998","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/BF00178720","article-title":"Morphine-6-O-beta-D-glucuronide but not morphine-3-O-beta-D-glucuronide binds to mu-, delta- and kappa- specific opioid binding sites in cerebral membranes","volume":"354","author":"L\u00f6ser","year":"1996","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib27","first-page":"484","article-title":"Comparison of the respiratory depression induced by morphine and morphine-6-glucuronide","volume":"62","author":"Thompson","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1749-6632.1986.tb14624.x","article-title":"Multiple morphine and enkephalin receptors: biochemical and pharmacological aspects","volume":"467","author":"Pasternak","year":"1986","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002826-199302000-00001","article-title":"Pharmacological mechanisms of opioid analgesics","volume":"16","author":"Pasternak","year":"1993","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib30","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/00000542-200005000-00038","article-title":"Insidious intoxication after morphine treatment in renal failure: Delayed onset of morphine-6-glucuronide action","volume":"92","author":"Angst","year":"2000","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib31","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1046\/j.1365-2044.2002.02624_2.x","article-title":"Unwanted effects of morphine-6-glucoronide and morphine","volume":"57","author":"Cann","year":"2002","journal-title":"Anaesthesia"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib32","first-page":"145","article-title":"Respiratory depression following morphine and morphine-6-glucuronide in normal subjects","volume":"40","author":"Thompson","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2125.1989.tb05401.x","article-title":"Long lasting respiratory depression induced by morphine-6-glucuronide?","volume":"27","author":"Hasselstr\u00f6m","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0022-3565(24)36555-3","article-title":"Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6beta-glucuronide antinociception","volume":"281","author":"Rossi","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0014-5793(95)00757-Z","article-title":"Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6 beta-glucuronide receptor","volume":"369","author":"Rossi","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib36","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1213\/00000539-199611000-00027","article-title":"A comparison of intrathecal morphine-6-glucuronide and intrathecal morphine sulfate as analgesics for total hip replacement","volume":"83","author":"Grace","year":"1996","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib37","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/bja\/64.5.547","article-title":"Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine","volume":"64","author":"Hanna","year":"1990","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib38","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(87)91083-X","article-title":"Explanation for potency of repeated oral doses of morphine?","volume":"2","author":"Hanks","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/00912700222011508","article-title":"Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers","volume":"42","author":"Murthy","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib40","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/clpt.1992.42","article-title":"The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function","volume":"51","author":"Portenoy","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib41","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1365-2125.1992.tb04121.x","article-title":"The analgesic activity of morphine-6-glucuronide","volume":"34","author":"Osborne","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/oxfordjournals.bja.a013391","article-title":"Analgesic action of i.v. morphine-6-glucuronide in healthy volunteers","volume":"84","author":"Buetler","year":"2000","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib43","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1067\/mcp.2000.111934","article-title":"Randomized placebo controlled trial of the activity of the morphine glucuronides","volume":"68","author":"Penson","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib44","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1097\/00000542-199712000-00014","article-title":"Lack of analgesic activity of morphine-6-glucuronide after short-term intravenous administration in healthy volunteers","volume":"87","author":"L\u00f6tsch","year":"1997","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib45","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00000542-200002000-00015","article-title":"Preemptive intravenous morphine-6-glucuronide is ineffective for postoperative pain relief","volume":"92","author":"Motamed","year":"2000","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib46","unstructured":"Peat SJ, Hanna MH, Durcan M, Fung M. Morphine-6-glucuronide in post operative pain (Abstract). The ninth world congress of pain, 2000: 334\u2013335."},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib47","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2165\/00003088-199324040-00007","article-title":"Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations","volume":"24","author":"Hasselstr\u00f6m","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1067\/mcp.2003.5","article-title":"Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers","volume":"73","author":"Skarke","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib49","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1136\/bmj.292.6535.1548","article-title":"Morphine intoxication in renal failure: the role of morphine-6- glucuronide","volume":"292","author":"Osborne","year":"1986","journal-title":"Br Med J Clin Res Ed"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/096032719000900509","article-title":"Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure","volume":"9","author":"Bodd","year":"1990","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0304-3959(94)00148-8","article-title":"Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients","volume":"61","author":"Tiseo","year":"1995","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib52","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/00000542-200112000-00009","article-title":"The transfer half-life of morphine-6-beta-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers","volume":"95","author":"L\u00f6tsch","year":"2001","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0022-3565(25)20113-6","article-title":"Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat","volume":"278","author":"Bickel","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib54","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/brain\/awg115","article-title":"Peripheral opioid analgesia in experimental human pain models","volume":"126","author":"Tegeder","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/brain\/117.2.385","article-title":"Different patterns of hyperalgesia induced by experimental inflammation in human skin","volume":"117","author":"Kilo","year":"1994","journal-title":"Brain"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib56","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJM199506223322506","article-title":"The control of pain in peripheral tissue by opioids","volume":"332","author":"Stein","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib57","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1213\/00000539-199301000-00031","article-title":"Peripheral mechanisms of opioid analgesia","volume":"76","author":"Stein","year":"1993","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib58","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0006-2952(01)00761-4","article-title":"Morphine-6beta-glucuronide and morphine-3-glucuronide, opioid receptor agonists with different potencies","volume":"62","author":"Ulens","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0014-2999(91)90199-Z","article-title":"Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine- 3-glucuronide","volume":"193","author":"Gong","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib60","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0024-3205(94)00552-4","article-title":"The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex","volume":"54","author":"Bartlett","year":"1994","journal-title":"Life Sci"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0024-3205(99)00239-8","article-title":"Brain region-specific studies of the excitatory behavioral effects of morphine-3-glucuronide","volume":"65","author":"Halliday","year":"1999","journal-title":"Life Sci"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib62","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1046\/j.1440-1681.2000.03290.x","article-title":"Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites","volume":"27","author":"Smith","year":"2000","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib63","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/bmj.319.7210.627","article-title":"Morphine induced allodynia in a child with brain tumour","volume":"319","author":"Heger","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib64","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0304-3959(95)00198-0","article-title":"Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved?","volume":"65","author":"Faura","year":"1996","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib65","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1021\/js980056f","article-title":"Morphine-3-glucuronide has a minor effect on morphine antinociception. Pharmacodynamic modeling","volume":"87","author":"Gardmark","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib66","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0006-2952(97)00086-5","article-title":"Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception","volume":"53","author":"Ouellet","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib67","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0196-9781(96)00215-X","article-title":"Effects of morphine-3-glucuronide on the antinociceptive activity of peptide and nonpeptide opioid receptor agonists in mice","volume":"17","author":"Bian","year":"1996","journal-title":"Peptides"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib68","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0014-2999(93)90441-J","article-title":"Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats","volume":"249","author":"Suzuki","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib69","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/jps.1131","article-title":"Limited phase I study of morphine-3-glucuronide","volume":"90","author":"Penson","year":"2001","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib70","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0885-3924(97)00020-1","article-title":"Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients","volume":"14","author":"Ashby","year":"1997","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib71","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s002280050368","article-title":"Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol","volume":"53","author":"Paar","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib72","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/0091270002042001002","article-title":"Concordance between tramadol and dextromethorphan parent\/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation","volume":"42","author":"Abdel-Rahman","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib73","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s002100000266","article-title":"Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor","volume":"362","author":"Gillen","year":"2000","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib74","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0014-2999(96)00770-4","article-title":"Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells","volume":"316","author":"Lai","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib75","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1476-5381.1992.tb14226.x","article-title":"Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro","volume":"105","author":"Driessen","year":"1992","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib76","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1476-5381.1993.tb12882.x","article-title":"Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro","volume":"108","author":"Driessen","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib77","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-3565(25)11227-5","article-title":"Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an \u2018atypical\u2019 opioid analgesic","volume":"260","author":"Raffa","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0006-8993(85)90719-X","article-title":"Studies on pain. Effects of morphine on a spinal nociceptive flexion reflex and related pain sensation in man","volume":"331","author":"Willer","year":"1985","journal-title":"Brain Res"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib79","first-page":"2241","article-title":"[Duality of the analgesic effect of tramadol in humans]","volume":"123","author":"Collart","year":"1993","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib80","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0009-9236(96)90211-8","article-title":"The hypoalgesic effect of tramadol in relation to CYP2D6","volume":"60","author":"Poulsen","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib81","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0304-3959(03)00212-4","article-title":"Impact of CYP2D6 genotype on postoperative tramadol analgesia","volume":"105","author":"Stamer","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib82","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-3565(25)39454-1","article-title":"Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol","volume":"267","author":"Raffa","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib83","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/bja\/79.3.352","article-title":"Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus","volume":"79","author":"Bamigbade","year":"1997","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib84","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/bja\/83.6.909","article-title":"Effects of tramadol stereoisomers on norepinephrine efflux and uptake in the rat locus coeruleus measured by real time voltammetry","volume":"83","author":"Halfpenny","year":"1999","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib85","first-page":"1553","article-title":"Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans","volume":"94","author":"Arcioni","year":"2002","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib86","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/00000539-200105000-00045","article-title":"The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron","volume":"92","author":"De Witte","year":"2001","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib87","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0304-3959(00)00299-2","article-title":"Pindolol, a beta-adrenoceptor blocker\/5-hydroxytryptamine(1A\/1B) antagonist, enhances the analgesic effect of tramadol","volume":"88","author":"Rojas-Corrales","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib88","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0014-2999(02)01647-3","article-title":"The antinociceptive effect of tramadol in the formalin test is mediated by the serotonergic component","volume":"445","author":"Oliva","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib89","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2125.1996.tb00152.x","article-title":"Contribution of monoaminergic modulation to the analgesic effect of tramadol","volume":"41","author":"Desmeules","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib90","first-page":"1283","article-title":"Pharmacokinetics of tilidine and metabolites in man","volume":"39","author":"Vollmer","year":"1989","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib91","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/j.1552-4604.1976.tb02401.x","article-title":"The clinical pharmacology of meperidine\u2014comparison of routes of administration","volume":"16","author":"Stambaugh","year":"1976","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib92","doi-asserted-by":"crossref","first-page":"548","DOI":"10.7326\/0003-4819-98-4-548","article-title":"Meperidine and central neurotoxicity","volume":"98","author":"Hershey","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib93","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/j.1875-9114.1994.tb02815.x","article-title":"Central nervous system toxicity associated with meperidine use in hepatic disease","volume":"14","author":"Danziger","year":"1994","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib94","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/15563659409017968","article-title":"Meperidine neurotoxicity after organ transplantation","volume":"32","author":"Adair","year":"1994","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib95","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0887-8994(96)00062-8","article-title":"Acute neurotoxicity of meperidine in an infant","volume":"14","author":"Saneto","year":"1996","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib96","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00000433-199203000-00009","article-title":"Lethal effects of normeperidine","volume":"13","author":"Jiraki","year":"1992","journal-title":"Am J Forensic Med Pathol"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib97","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0272-6386(00)70314-3","article-title":"Successful treatment of normeperidine neurotoxicity by hemodialysis","volume":"35","author":"Hassan","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib98","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/00498250110119090","article-title":"Hydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patient","volume":"32","author":"Zheng","year":"2002","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib99","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0024-3205(01)01133-X","article-title":"Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide","volume":"69","author":"Wright","year":"2001","journal-title":"Life Sci"},{"key":"10.1016\/j.jpainsymman.2005.01.004_bib100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0024-3205(98)00288-4","article-title":"Hydromorphone-3-glucuronide: biochemical synthesis and preliminary pharmacological evaluation","volume":"63","author":"Wright","year":"1998","journal-title":"Life Sci"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392405000308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392405000308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:55:00Z","timestamp":1760129700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392405000308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0885392405000308"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2005.01.004","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opioid Metabolites","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2005.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}